News
It also aligns with a strategy that 23andMe had been pursuing for years. The Regeneron Biotechnology company logo is seen displayed on a smartphone. (Igor Golovniov/SOPA Images/LightRocket via ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback